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Abstract 
The Quality-Time-Cost Iron triangle is in the middle of a pharmaceutical commercial 
production process. However, nowadays pharmaceutical companies try to optimize the 
security level of sterility assurance, available capacity and costs, looking for innovative 
technologies in order to improve their processes.  
Within this master thesis, the possibility to transfer active pharmaceutical ingredient 
solutions with a peristaltic pump and with overpressure in combination with a combined 
thawing and transfer disposable tube was tested. Moreover, the transfer speeds of three 
combined thawing and transfer disposable tubes in combination with the two transfer 
methods were measured in order to decide which combined disposable tube and which 
method is more suitable for the transfer of active pharmaceutical ingredient solutions and 
therefore, see if it is advantageous to replace the current single thawing and single transfer 
disposable tubes, taking also into account other additional factors.  
It is possible to transfer active pharmaceutical ingredient with a peristaltic pump and 
overpressure. However, the use of an optimized combined thawing and transfer 
disposable tube in combination with the overpressure transfer method would be an 
innovative process and would bring quality and efficiency to a pharmaceutical sterile drug 
product manufacturing process. 
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Resumo 
O triângulo de ferro qualidade-tempo-custo está no seio do processo farmacêutico de 
produção comercial. No entanto, nos nossos dias, as empresas farmacêuticas tentam 
otimizar o nível de segurança de garantia da esterilização, a capacidade disponível e os 
custos, procurando melhorar os seus processos produtivos por recurso a tecnologias 
inovadoras. 
No âmbito desta tese, foi testada a possibilidade de transferência de soluções de 
ingredientes farmacêuticos ativos, por recurso a dois métodos de transferência de fluidos, 
bomba peristáltica e sobrepressão, em combinação com um tubo descartável de 
descongelamento e transferência. Além disso, foram medidas as velocidades de 
transferência através dos dois métodos utilizando três alternativas de tubos descartáveis 
combinados de descongelamento e transferência, de forma a decidir qual o método e o 
tubo descartável combinado mais adequados para a transferência de soluções de 
ingredientes farmacêuticos ativos e, por conseguinte, verificar se é vantajoso proceder à 
substituição dos atuais tubos descartáveis, um de descongelamento e outro de 
transferência, tendo igualmente em consideração outros fatores adicionais necessários à 
tomada de decisão. 
É possível transferir ingredientes farmacêuticos ativos através de bomba peristáltica e 
através de sobrepressão. Contudo, a utilização otimizada de um tubo descartável 
combinado de descongelamento e transferência, empregando o método de transferência 
de sobrepressão, seria um processo inovador que traria qualidade e eficiência ao processo 
de produção de produtos farmacêuticos estéreis. 
 
 
 
 
 
Palavras-chave: tecnologias descartáveis, tubos descartáveis combinados de 
descongelamento e transferência, bomba peristáltica, sobrepressão 
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Glossary 
Active Pharmaceutical Ingredient - any substance or combination of substances used 
in a finished pharmaceutical product, intended to furnish pharmacological activity or to 
otherwise have direct effect in the diagnosis, cure, mitigation, treatment or prevention of 
disease, or to have direct effect in restoring, correcting or modifying physiological 
functions in human beings. 
Aseptic - free of pathogenic microorganisms. 
Batch - a quantity of any drug produced during a given cycle of manufacture. 
Basic clean rooms – clean rooms that have control of airflow, air filtration, air velocity, 
air changes, air pressure, airborne particulates, temperature, humidity and 
microorganisms.  
Bioburden - population of viable microorganisms on or in raw materials, products, and 
labeling/packaging materials determined before sterilization. 
Clean in place - cleaning of equipment in its assembled condition and at its location. This 
cleaning may be an automatic process or manual. Whatever the method, it must comply 
with the stringent hygiene regulations of the pharmaceutical industries.  
Clean room area - an area (or room or zone) with defined environmental control of 
particulate and microbial contamination, constructed and used in such a way as to reduce 
the introduction, generation and retention of contaminants within the area. 
Containment - a process or device to contain product, dust or contaminants in one zone, 
preventing it from escaping to another zone. 
Contamination - The undesired introduction of impurities of a chemical or 
microbiological nature, or of foreign matter, into or on to a starting material, intermediate 
or pharmaceutical product during handling, production, sampling, packaging or 
repackaging, storage or transportation. 
Class C – a clean area for carrying out less critical stages in the manufacture of sterile 
products. In this clean area personal must take hair cover, beard cover, face mask, a 
general protective suit, gathered at the wrists and with high neck, shoe covers and gloves. 
This area has a maximum permitted number of particles per m3 at rest and in operation 
and has recommended limits for microbial contamination. The maximum permitted 
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number of particles per m3 equal to or greater than 0,5 µm is at rest 352000 and is in 
operation 3520000. The maximum permitted number of particles per m3 equal to or 
greater than 5 µm is at rest 2900 and is in operation 29000. The recommended limits for 
microbial contamination in contact plates (Ø 55mm) are 25 cfu/plate. 
Cross contamination - contamination of a starting material, intermediate product or 
finished product with another starting material or product during production or due to 
microorganisms. 
Current Good Manufacturing Practices – is the aspect of quality assurance that ensures 
that medicinal products are consistently produced and controlled to the quality standards 
appropriate to their intended use and as required by the product specification. 
Class D - a clean area for carrying out less critical stages in the manufacture of sterile 
products. In this clean area personal must take hair cover, beard cover, a general 
protective suit and shoe covers. This area has a maximum permitted number of particles 
per m3 at rest and in operation and has recommended limits for microbial contamination. 
The maximum permitted number of particles per m3 equal to or greater than 0,5 µm is at 
rest 3520000 and is not defined in operation. The maximum permitted number of particles 
per m3 equal to or greater than 5 µm is at rest 29000 and is not defined in operation. The 
recommended limits for microbial contamination in contact plates (Ø 55mm) are 50 
cfu/plate. 
Endotoxin - lipopolysaccharide contained within the outer membrane of Gram-negative 
bacteria that may lead to pyrogenic reactions and other biological activities in humans. 
Gamma irradiation – the operation of exposing a material to gamma rays in order to 
sterilize. 
Gray space – non-defined clean room area. 
LAL test - used for the detection and quantification of bacterial endotoxins. 
Process qualification - confirming that the manufacturing process as designed is capable 
of reproducible commercial manufacturing. 
Process validation - documented evidence which provides a high degree of assurance 
that a specific process will consistently result in a product that meets its predetermined 
specifications and quality characteristics. Process validation is a requirement of current 
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Good Manufacturing Practices. Process validation involves a series of activities taking 
place over the lifecycle of the product and process. 
Qualification - action of proving and documenting that equipment or ancillary systems are 
properly installed, work correctly, and actually lead to the expected results. Qualification is 
part of validation, but the individual qualification steps alone do not constitute process 
validation. 
Sanitization - process of decontamination that reduces viable microorganisms to a 
defined acceptance level.  
Shelf life - The period of time during which a pharmaceutical product, if stored correctly, 
is expected to comply with the specification as determined by stability studies on a 
number of batches of the product. The shelf-life is used to establish the expiry date of 
each batch. 
Spalling – is the removal of small particulate matter from the inner wall of flexible tubing 
when subjected to repeated deformation and flexing. 
Standard operating procedures – an authorized, written procedure giving instructions 
for performing operations not necessarily specific to a given product but of a more general 
nature (e.g. equipment operation, maintenance and cleaning, validation, cleaning of 
premises and environmental control, sampling and inspection). 
Sterile – complete absence of microorganisms. 
Sterilization - complete destruction or removal of all microorganisms including spore-
forming and non-spore-forming bacteria, viruses, fungi, and protozoa. 
Sterilization in place – sterilization of equipment in its assembled condition and at its 
location. 
Validation - action of proving and documenting that any process, procedure or method 
actually and consistently leads to the expected results. It includes the qualification of 
systems and equipment. In general, an entire process is validated. 
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1. Introduction 
1.1.  Disposable technologies 
It has been about a decade since disposable products were introduced to the 
biomanufacturing industry. While disposables have been examined for years in less 
regulated environments, disposable manufacturers had to demonstrate their benefits and 
qualities to convince biomanufacturers to try them (Mintz, C. 2009; Whitford, W. G., 
2010). 
Pharmaceutical drug products should be produced with efficiency (reduced costs and less 
production time) and with high quality according to current Good Manufacturing 
Practices (cGMP) as shown in the iron triangle (see figure 1) (Valle, C., 2009; Sandle, T., 
& Saghee, M. R., 2011). Quality-Time-Cost is in the middle of the development process. 
At each verification point, choices have to be made, based on Quality-Time-Cost. There 
must be a balance between the three pillars of the triangle. For example too little time 
could lead to poor quality, which can prove very expensive later on. Therefore, ways have 
to be found to improve quality and still cut on time and costs (Legrand, B., 2004). 
 
 
 
 
 
 
However, the presence of microbiological contamination can affect the quality and the 
efficiency leading to batch rejection. Therefore, an emphasis on risk reduction should be 
an essential component of sterile product manufacturing. A focus on high quality 
operating clean rooms, trained staff, the use of sterilized clean room items and recent 
technologies are examples of what can be done to support this goal (Sandle, T., & Saghee, 
M. R., 2011). 
The development from basic clean rooms to novel clean room technologies over the last 
years has resulted in a reduction on the risk of product contamination and in a 
Figure 1. The Iron Triangle. Adapted 
from Atkinson, R. (1999). 
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simplification of the process operation. These novel technologies include the following: 
barrier isolated systems and RABS (restricted access barrier systems) to protect the 
aseptic filling; methods to protect the product from personnel contamination such as 
particle reducing air showers; sanitization and sterilization methods to decontaminate 
clean rooms and sterile disposable technologies. The use of disposable technologies 
allowed pharmaceutical companies to substitute equipment that needs to be sterilised by 
disposable items (Sandle, T., & Saghee, M. R., 2011). 
Nowadays pharmaceutical companies are under pressure to increase productivity and 
profitability. In addition, there is a concern about costs, available capacity and sterility 
assurance, forcing them to look for available technologies in order to optimize their 
processes (Sinclair, A., & Monge, M., 2002; Aranha, H., 2004). As a consequence, some 
pharmaceutical companies have incorporated disposables technologies in the 
biopharmaceutical and biotechnology sectors (Sandle, T., & Saghee, M. R., 2011). 
Single-use technologies, which are generally sterile, plastic items, have been adopted in 
order to replace traditional pharmaceutical processing items, like stainless steel that 
require cleaning, recycling and in-house sterilization (Sandle, T., & Saghee, M. R., 2011).  
Disposables are available in different formats and can be rigid or flexible. They are 
usually manufactured from plastic polymers approved by the Food and Drug 
Administration (FDA) (Eibl, D., Peuker, T., & Eibl, R., 2011; Sandle, T., & Saghee, M. 
R., 2011). The plastic items are especially suitable to pre-sterilization with gamma 
irradiation, between 25 and 50 kGy, because of the relative transparency of plastics to 
ionizing radiation, which allow a disposable to be sterilized without the risk of spreading 
the sterilizing agent throughout the fluid path. The sterilization cycles must achieve a 
Sterility Assurance Level of at least 10-6. This method of sterilization protects the 
disposable material, plastic, from degradation and eliminates the need for subsequent 
sterilization of the equipment. When gamma irradiation is used for sterilization it is 
important to take in consideration the appropriate irradiation dose and the inspection of 
the sterilized item for signs of degradation (Eibl, D., Peuker, T., & Eibl, R., 2011; Sandle, 
T., & Saghee, M. R., 2011; Repetto, R., et al., 2014). Other sterilization methods are 
acceptable to sterilize disposables. Examples of other sterilization methods are: 
autoclaving that is often used to sterilize components assembled by end-users and gas 
sterilization using ethylene oxide. However, gas sterilization is not widely used since by-
products can be formed and some ethylene oxide can be retained. Each method is 
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appropriate for different applications and should be evaluated for suitability (Repetto, R., 
et al., 2014). 
1.1.1.  Examples of disposable technologies  
Table 1. Common types of disposable technologies used in the biopharmaceutical industry. 
Adapted from Sandle, T., & Saghee, M. R. (2011).T 
 
 
 
 
 
 
 
 
 
When using a disposable unit, there are a number of factors that should be considered, 
such as the number of manufacturing campaigns per year, the size of the production unit 
(volume and capacity requirements), the operating conditions (pressure, temperature and 
operation period) and the compatibility of the product with the disposable unit (Aranha, 
H., 2004).  
1.1.2.  Disadvantages 
The main issue of using disposables that drug manufacturers and FDA are more 
concerned about, is the release of leachables and extractables (Kauffman, J. S., 2006; 
Mintz, C., 2009). Leachables are chemical components that migrate naturally over time, 
under normal conditions, from the disposable to the drug product formulation, when there 
is contact between both (Kauffman, J. S., 2006; Eibl, D., Peuker, T., & Eibl, R., 2011). 
The level and variability of the gamma irradiation that is used for the sterilisation of 
disposables can affect the level of leachables that migrate to the drug product formulation 
(Rao, G., Moreira, A., & Brorson, K., 2009). Extractables are chemical components that 
are extracted from the disposable that enters in contact with the drug product formulation 
when exposed to extreme conditions such as harsh solvents or high temperatures 
(Kauffman, J. S., 2006; Eibl, D., Peuker, T., & Eibl, R., 2011). The presence of leachables 
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and/or extractables can modify the safety, quality, identity, strength or purity of the drug 
products. Therefore, the FDA offers guidance for protection against leachables and 
extractables (Kauffman, J. S., 2006). 
1.1.3.  Advantages 
The adoption of disposables has been increasing due to a variety of advantages over 
traditional stainless steel systems, which include: decreased risk of cross-contamination, 
increased assurance of sterility, safety considerations, process efficiencies, cost saving 
and others (Aranha, H., 2004, Mintz, C. 2009; Sandle, T., & Saghee, M. R., 2011). 
Cross-contamination 
Cross contamination might result from microbiological contamination that can be 
transferred from one batch to another, and from product adulteration, which means that 
chemical residues can also be transferred from one batch to another. Disposables decrease 
the risk of cross-contamination because they are single used and consequently not used 
for further operations (Sandle, T., & Saghee, M. R., 2011).  
Sterility assurance 
The assurance of sterility is achieved due to a reduction of cross-transference of 
microorganisms that diminishes the risk of environmental microbial contamination and 
also due to a reduction of inadequate sterilisation cycles. The use of disposables avoid 
cross contamination since the need to clean components disappears, thus reducing manual 
handling. In addition, it allows the pharmaceutical companies to distance themselves from 
equipment that needs to be sterilized or offer a risk with their transfer to clean rooms. A 
reduction of microbial contamination is also achieved since structural integrity tests 
(testing for leaks) of disposable technologies are also made by the manufacturers and by 
the pharmaceutical company (Sandle, T., & Saghee, M. R., 2011; Jenness, E., & Gupta, 
V., 2011; Repetto, R., et al., 2014). 
Safety considerations 
The use of disposables is safe for the product and for the operator. On one hand, it is safe 
for the product because it reduces cross contamination as it is single used. In addition, the 
potential for microbial contamination is decreased because the intervention of the 
operator is less dependent since there is a reduction in assembly and handling of the 
system. On the other hand, it is safe for the operator to use single use systems when he 
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manipulates cytotoxic drugs, so called highly potent drugs or radiolabeled chemicals. The 
handling of the operator with hazardous active pharmaceutical ingredients (API) is 
diminished because single use systems don’t need clean in place (CIP) and sterilization 
in place (SIP) operations. Thus, disposable systems protect the operator from materials 
that can compromise his health and are in the best interest of manufacturing personnel 
(Aranha, H., 2004; Sandle, T., & Saghee, M. R., 2011). 
Process efficiencies 
The use of disposables has advantages with regard to process efficiencies in comparison 
with reusable stainless steel systems. Reusable stainless steel systems lead to equipment 
support and routine inspections that need labour, time, effort and money. With the use of 
disposables labour and time can be saved by decreasing operator dependence so that 
operators and other resources can be used for other tasks. Disposables also reduce process 
downtime and eliminate CIP and SIP, which save time, energy and costs. Time is also 
saved because qualification and validation are facilitated (Aranha, H., 2004; Eibl, D., 
Peuker, T., & Eibl, R., 2011). Moreover they save waste disposal and quantities of 
detergents and other cleaning chemicals that are used. The most important advantage is 
faster turnaround times. There is a reduction of the time taken to obtain a new batch ready 
for processing (Aranha, H., 2004; Mintz, C. 2009; Sandle, T., & Saghee, M. R., 2011).  
Costs savings 
One of the reasons that explain cost savings is the elimination of contamination events 
that lead to batch rejection and process downtime (Eibl, D., Peuker, T., & Eibl, R., 2011). 
Additionally, costs are reduced given that smaller batch sizes are possible to produce. 
Disposable technologies are also capable to operate outside the clean rooms, which are 
expensive (Valle, C., 2009). The costs are also reduced since the use of expansive 
cleaning procedures (corrosive chemicals, water for injection and sterilization 
procedures) are no longer required as disposables are pre-sterilized and discarded (Eibl, 
D., Peuker, T., & Eibl, R., 2011). With the use of disposables there is also a reduction of 
costs in installation, in process qualification and validation and in maintenance 
requirements (Wong, R., 2004; Eibl, D., Peuker, T., & Eibl, R., 2011; Sandle, T., & 
Saghee, M. R., 2011). 
Design/Optimization/Introduction of Disposables for Biotech Drug Product Processes 
22 
Therefore, the use of disposable technologies not only increases quality since these 
technologies decrease cross contamination, assure sterility and are safer but also reduces 
costs and time.  
1.1.4.  Qualification and Validation 
GMP regulations that are involved with the production of drugs and active pharmaceutical 
ingredients (API´s) are supported by the FDA regulations 21 CFR Parts 210 and 211 and 
internationally they are supported by the European Union directive 356 (Day, N., 2004). 
Disposable technologies are manufactured according to cGMP, and must be qualified and 
validated to guarantee that the equipment is not reactive, additive or absorptive, which is 
important to assure that the safety, identity, strength, quality or purity of the API is not 
affected (CFR, 2014). 
Disposable technologies are manufactured with pharmaceutical grade polymeric 
materials that are tested to meet the requirements of USP<87>, USP<88>, USP<661> 
ISO 10993 and EP <3.1.9> (Creasey, J. & Thibion, V., 2013; Mueller, D., 2014). The 
qualification and validation methods have to demonstrate that the disposable is reliable, 
robust and safe (Belongia, B. M., & Allay, J. A., 2006). 
Single use systems are sterilized with gamma irradiation, which can decrease the shelf 
life of disposables and can accelerate the degradation of the polymeric substances. 
Qualification tests must be done to determine the effects of irradiation and the stability of 
the polymer used. Some qualification tests are (Aranha, H., 2004; Jornitz, M. W., Cappia, 
J.-M. & Meltzer, T. H., 2009; Jornitz, M. W., Szarafinski, D., & Peuker, T., 2012; 
Mueller, D., 2014): 
 Biocompatibility testing: 
o USP ‹87› biological reactivity tests, in vitro, 
o USP ‹88› biological reactivity tests, in vivo. 
 Mechanical properties:  
o tensile strength,  
o elongation at break,  
o seal strength,  
o air leak test. 
 Gas transmission properties:  
o ASTM D3985: oxygen,  
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o ASTM F1249: water vapour. 
 USP ‹661› test for plastics.  
 European Pharmacopeia (EP) <3.1.7.>: Ethylene vinyl acetate (EVA) for containers 
and tubing. 
 European Pharmacopeia (EP) <3.1.9.>: Silicone elastomers for closures and tubing. 
 European Pharmacopeia (EP) <5.2.8.>: Minimizing the risk of transmitting animal 
spongiform encephalopathy agents via human and veterinary medicinal products. 
 Total organic carbon (TOC) analysis. 
 pH and conductivity. 
 Extractable and leachable tests with standard solutions. 
 Chemical compatibility testing. 
 Protein adsorption studies. 
 Endotoxin testing. 
 Gamma irradiation sterilization validation. 
 Bacterial ingress test. 
These tests are performed by the disposable technologies manufacturer under standard 
setting and solutions, so they only serve as guidance for the pharmaceutical company that 
buys the disposable technologies. Thus, before implementing the disposable technologies 
in the manufacturing process, the system users must validate them under specific 
requirements and process conditions (Aranha, H., 2004; Jornitz, M. W., Cappia, J.-M. & 
Meltzer, T. H., 2009; Jornitz, M. W., Szarafinski, D., & Peuker, T., 2012).  
1.1.5.  Environmental impact 
The balance of ecosystems can be significantly affected by human activities and therefore 
have health, aesthetic and economic consequences to us. Consequently, sustainability is 
an important issue and companies must respect laws and regulations that are related to 
their business activities (Whitford, W. G., 2014). Companies should provide information 
on the environmental impact and sustainability of their manufacturing systems (Rawlings, 
B., & Pora, H., 2009). The environmental evaluation can be enabled through guidelines 
from industrial organization (ex: Bio Process Systems Alliance (BPSA)), regulatory 
guidelines and directives, data from suppliers and manufacturers and published articles, 
reviews, and case studies (Rawlings, B., & Pora, H., 2009). 
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Table 2. Recycling advantages and constraints. Adapted from Pora, H., & Rawlings, B. (2009). 
The environmental impact of disposable technologies has become a concern in recent 
years (Rawlings, B., & Pora, H., 2009; Pora, H., & Rawlings, B., 2009). Thus, 
manufacturers should choose recyclable materials of construction for disposable systems 
instead of using materials made from non-renewable feedstocks (Rao, G., Moreira, A., & 
Brorson, K., 2009). Disposable systems should be designed and manufactured to ensure 
a minimum environmental impact and a maximum recyclability of waste (Rao, G., 
Moreira, A., & Brorson, K., 2009; Pora, H., & Rawlings, B., 2009).  
Another concern is the environmental impact of currently used disposal methods, which 
should consider the legislation in force to protect the environment and guarantee 
industrial sustainability. There are three major solid-waste disposal methods for 
disposable systems: 1) recycling options, which include the reuse of components, the 
reprocessing of recycled material and the production of liquid fuel; 2) incineration, with 
or without energy recovery; 3) landfills (non-hazardous waste, hazardous waste). The 
following tables summarize the advantages and constraints of the methods above 
mentioned (Pora, H., & Rawlings, B., 2009): 
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Table 4. Landfill advantages and constraints. Adapted from Pora, H., & Rawlings, B. (2009). 
Table 3. Incineration advantages and constraints. Adapted from Pora, H., & Rawlings, B. (2009). 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Taking into account the three disposal methods presented, the optimal choice would be 
the one with the lowest environmental impact. In order to help making this choice, a 
decision tree can be used, as shown below (Pora, H., & Rawlings, B., 2009): 
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Figure 2. Decision tree for management of solid waste (Pora, H., & Rawlings, 
B., 2009).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2.  Highly potent drugs 
In the recent years, the pharmaceutical industry has developed new and more potent API 
due to advances in clinical pharmacology and oncology research (Mari, G., Moccaldi, A., 
& Ludovisi, G., 2005; Karmarkar, A. B., 2012). Highly potent active pharmaceutical 
ingredients (HPAPI) are becoming more selective in their interaction with biological 
targets and are particularly effective at small doses (Harris, R., 2012; Bowman, M., 2013). 
Examples of HPAPIs are hormones, cytostatics, narcotics and retinoids (Bowman, M., 
2013; Denk, R., 2014). In addition, there is a new generation of highly potent drugs called 
antibody drug conjugates (ADCs) which are a monoclonal antibody conjugated with a 
HPAPI like a cytotoxic. The ADCs are selective in their interaction with the target and 
differentiate the healthy tissue from the diseased tissue, since the monoclonal antibody is 
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joined to the HPAPI by a short linker molecule, which is designed to break down at the 
active site and release the cytotoxic (Bormett, D., 2008; Lonza, 2012; Wooge, C., 2014)  
Every API must be evaluated and classified to assess potential toxicity, potency and 
potential hazards so that the level of containment that is required can be determined 
(Bormett, D., 2008). The drug substances can be classified according to their potency 
based on the use of occupational exposure limits (OEL) or occupational exposure bands 
(OEB) (Calkins, T., 2010; Wollowitz, S., 2010; Harris, R., 2012). The OEL is given in 
microgram (µg) per cubic meter (m3) or milligram (mg) per cubic meter (m3) and as the 
most likely and toxic route is by inhalation it is defined as the air concentration of the 
compound that can be inhaled by a worker over an 8h working day, 40 hours a week 
without adverse effects (Wollowitz, S., 2010; Denk, R., 2014). A lower value of OEL 
means a more potent compound which requires a higher level of containment (Van 
Arnum, P., 2009). The OEB group together substances by an approximate hazard level 
and this dictate the handling containment required to work with the substances 
(Wollowitz, S., 2010; Bowman, M., 2013). In the last years, a number of systems have 
been proposed to classify APIs (Harris, R., 2012). The industry uses different category 
systems ranging from three to six - category systems (Farris, J. P., Ader, A. W., & Ku, R. 
H., 2006; Calkins, T., 2010). There are also companies that developed their own category 
system, according to their equipment and facilities (Bowman, M., 2013). There are 
different category systems because companies have different products, facilities, 
equipment and processes (Farris, J. P., Ader, A. W., & Ku, R. H., 2006). The system that 
is more frequently used is the four category system, the SafeBridge System and its 
evaluation and categorisation are described in table 5 (Farris, J. P., Ader, A. W., & Ku, 
R. H., 2006; Harris, R., 2012; Bowman, M., 2013). 
 
 
 
 
 
Active pharmaceutical ingredients can be potent when (Bormett, D., 2008; Bowman, M., 
2013): 
Table 5. High potency API evaluation and categorization. Adapted from Farris, J. P., Ader, A. 
W., & Ku, R. H. (2006), Harris, R. (2012), Bowman, M. (2013). 
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1. The active pharmaceutical ingredient has an OEL of ≤ 10 µg/m3 of air as an 8 
hour time weighted average. 
2. The active pharmaceutical ingredient has a therapeutic dose of ≤ 10 mg/day. 
3. The dose of 1 mg/kg/day of active pharmaceutical ingredient produce serious 
toxicity in laboratory animals. 
4. The active pharmaceutical ingredient has high selectivity and/or has the potential 
to cause cancer, mutations, developmental effects or reproductive toxicity at low 
doses. 
5. It is a novel compound of unknown toxicity. 
The handling with highly potent active pharmaceutical ingredients requires a substantial 
investment in specialized containment to guarantee that workers and the working 
environment are protected from exposure (Bormett, D., 2008). A safe handling with 
highly potent active pharmaceutical ingredients can be achieved by using standard 
operating procedures (SOPs), trained workers, containment equipments, personal 
protective equipment, process isolation, facility design and cGMP activities (Bormett, D., 
2008; Karmarkar, A. B., 2012). 
1.2.1.  Facility design 
Handling with highly potent active pharmaceutical ingredients requires specialized 
equipment to achieve containment and attention to safety. A facility should be designed 
with equipment such as isolators with laminar flow hoods and appropriate ventilation for 
potent compound handling to protect workers and to maintain the product sterile. The 
room pressure should be negative to its surrounding rooms to guarantee that the potent 
products are retained in the working environment. The air should also be filtrated so that 
escaping product is captured before its release to the external environment. To prevent 
cross contamination or concentration of materials, the airflow in the facility must be 
single pass. Process isolation and containment equipment are very important to ensure 
that an entire manufacturing process is carried out in closed systems (from raw materials 
to product packaging) so that the chances of operators exposure can be minimized (Van 
Arnum, P., 2009; Calkins, T., 2010; Wooge, C., 2014).  
The facility design for ADCs has to take in consideration that the HPAPI must be 
contained under negative pressure, but the antibody components and the final drug 
product should be handled under positive pressure to prevent microbial and particle 
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contamination. Therefore, the handling steps involving HPAPI should take place in an 
isolator in a separate room, where the air is under negative pressure. HPAPIs can only 
leave this room if they are in solution, because this removes the risk of airborne 
contamination and the chances of operators or environment contamination are much 
lower. The conjugation to an antibody occurs in a second room which is under positive 
pressure and therefore protects the product from external contamination. The conjugation 
reaction must still take place in a closed system that enables full containment of hazardous 
materials, because despite being in solution HPAPIs are still hazardous (Calkins, T., 
2010; Wooge, C., 2014).  
Disposable technologies are a suitable option for handling with HPAPIs as they can 
improve containment. They protect and reduce the exposure of the operators from the 
compounds, they eliminate the need for extensive cleaning that potent drugs require and 
decrease cross contamination. The adoption of disposable technologies is of extreme 
importance in order to avoid the present risk of contamination of HPAPI in multiproduct 
facilities (Greb, E., 2010; Challener, C., 2014).  
1.3.  Cryo-vessel  
Cryo-vessels are large-scale cryo-preservation systems made of stainless steel containers 
from 50-300 L. They are divided in two compartments. The inner compartment contains 
the API solution, whereas the outer compartment, named double coat is for the circulation 
of silicon oil. They are systematically frozen and thawed with a well-controlled heat or 
cold transfer fluid (silicon oil) that circulates in the outer compartment and goes in the 
internal compartment through an inner tube snake with fins, which efficiently transfer 
heat or cold into the solution (Arnitz, T., & Liebig, C., 2011; Kantor, A., MacMillan, S., 
Ho, K., Tchessalov, S., & Warne, N., 2011; Kolhe, P., & Badkar, A., 2013).  
Cryo-vessels are used for freezing, storage, transport and thawing of API. The 
temperature storage can range from liquid storage at 2 – 8 °C to frozen storage down to -
50 °C. The liquid storage from 2 - 8 °C can affect the quality and lead to degradation of 
proteins. Therefore, frozen storage is indicated to guarantee a higher stability and longer 
shelf life of proteins, decrease microbial growth and eliminate the foam formation during 
transport (Webb, S. D., Webb, J. N., Hughes, T. G., Sesin, D. F., & Kincaid, A. C., 2002; 
Arnitz, T., & Liebig, C., 2011; Kantor, A., Tchessalov, S., & Warne, N., 2011; Desu, H. 
R., & Narishetty, S. T., 2013).  
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As proteins lack stability when in solution, it was considered convenient since a long 
time, to freeze them because of the need to store proteins for a large period of time. New 
approaches to the freezing and storage of proteins have been developed in which the 
freeze-thaw process is better controlled due to the emergence of large scale production of 
proteins (Kantor, A., Tchessalov, S., & Warne, N., 2011). 
Protein based API can be stored under a variety of conditions such as refrigerated liquids 
and spray dried powders. However, a considerable number of clinical and commercial 
API are stored in a frozen state (Kantor, A., Tchessalov, S., & Warne, N., 2011). 
There are three types of container closure system normally used for frozen API: plastic 
or stainless steel bottles between 1-5 L, plastic bags between 1-16 L and stainless steel 
cryo-vessels between 50-300 L. Although there has been a development of the systems, 
there is still a need for all these three systems depending on the nature of the drug 
substance, its volume and storage temperature (Kantor, A., Tchessalov, S., & Warne, N., 
2011; Kolhe, P., & Badkar, A., 2013). 
1.4.  Tubings and Connectors  
Nowadays the economic situation is an obstacle for the development of new drugs. As a 
challenge, the pharmaceutical companies have to review their manufacturing systems and 
find ways to make them more reliable, flexible and cost-effective. Therefore traditional 
stainless steel equipment has been replaced by pre-sterilized disposable technologies 
(Boehm, J., 2010).  
1.4.1.  Tubings 
Flexible tubings have gained more acceptance in recent years due to its low costs 
associated with validation, CIP and SIP (Spontak, R. J., & Patel, N. P., 2000; Colas, A., 
Malczewski, R., & Ulman, K., 2004).  
Tubings are involved in the manufacturing of pharmaceuticals and are currently used for 
fluid transfer, gas transfer, peristaltic pumping and filling operations. Tubings are made 
from various polymeric materials that may vary according to polymer class, molecular 
weight and additives. This variability confers a wide range of performance characteristics 
on the plastic materials. Examples of plastics that are commonly used are silicone and 
thermoplastic elastomer (Colas, A., 2001; Aranha, H., 2004).  
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Silicone can have diverse applications: as excipients in topical formulation, as excipients 
in controlled devices and in pharmaceutical manufacturing for siliconisation, as antifoam 
and for tubing. Silicone tubings are used in pharmaceutical manufacuturing operations 
for transfer processes. Two types of silicone tubings may be used: platinum-cured silicone 
tubings or peroxide-cured silicone tubings. It is preferable to use platinum-cured silicone 
tubings since it is naturally purer and it offer fewer leachables and extractables; they have 
smoother internal surfaces and it minimizes protein loss due to adhesion. Moreover 
peroxide cured tubings contain peroxide by-products that can be released and contaminate 
the transferred product (Colas, A., 2001, Aranha, H., 2004; AdvantaPure, 2013). The 
platinum-cured silicone tubings can have different applications such as in ultra-pure fluid 
transfer or in peristaltic pumps, where durability is required or in high/low pressure 
applications (Dow Corning). 
Tubings that can be heat sealed and welded are often needed at some point in the fluid 
path. Instead of using multiple materials in the different sections of the fluid path since 
not all materials have the required characteristics (for example: heat sealed and welded 
capacity), a material that meets the needed requirements of the customer can be selected. 
Tubing materials such as thermoplastic elastomer (combine the material properties of 
rubbers and plastics) meet the conditions that are often required.This kind of tubing is 
flexible, has a high purity, is less permeable and is a peristaltic pump tubing that may be 
welded and sealed, thus eliminating the use of multiple materials in a fluid path 
(AdvantaPure,  2013). Thermoplastic elastomer can be divided in two groups: multiblock 
copolymers which consist of soft elastomers and hard thermoplastic blocks such as 
thermoplastic polyurethane and blends (Shanks, R., & Kong, I., 2012). 
 
 
 
 
 
 
 
 
Table 6. Example of plastic used for tubing (Silicone). Adapted from Repetto, R., et al. (2014). 
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Other plastics that can be used for tubing:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 7. Example of plastics used for tubing (Thermoplastic elastomer). Adapted from Repetto, R., et al. 
(2014). 
Table 9. Examples of plastics used for tubing (Fluoropolymers). Adapted from Repetto, R., et al. (2014). 
Table 8. Example of plastic used for tubing (Copolymer). Adapted from Repetto, R., et al. (2014). 
Introduction 
33 
In the cGMP environment flexible tubing has to be qualified and validated. So, the tubing 
that are considered for single use application as well as for multiple use application need 
to meet FDA, ISO, USP, EP and ASTM standards. In case of an inspection in the US it 
is sufficient that the tubing meet the US standards and in case of an inspection in the 
Europe it is sufficient that the tubing meet the Euopean standards. Therefore, according 
to the country where it is manufactured and according to the delivery country the 
following standards should be fulfilled (Colas, A., Malczewski, R., & Ulman, K., 2004; 
Hunt, D. G., 2013; Mueller, D., 2014):  
US standards: 
 FDA G95-1 Memorandum: Required Biocompatibility Training and Toxicology 
Profiles for Evaluation of Medical Devices. 
 FDA 21 CFR 177.2600: Rubber articles intended for repeated use. 
 USP <85>: Bacterial Endotoxins Test. 
 USP <87>: Biological Reactivity Tests, In Vitro. 
 USP <88>: Biological Reactivity Tests, In Vivo, Classification of Plastics: Class V 
and VI. 
 USP <1663>: Extractables. 
 USP <1664>: Leachables. 
 ASTM F748-98: Standard Practice for Selecting Generic Biological Test Methods for 
Materials and Devices. 
International standards: 
 ISO 10993: Biological Evaluation of Medical Devices, Part 1: Evaluation and Testing. 
 ISO 10993: Biological Evaluation of Medical Devices, Part 5: Tests for in vitro 
cytotoxicity. 
 ISO 10993: Biological Evaluation of Medical Devices, Part 11: Tests for systemic 
toxicity. 
European standards: 
 EP <3.1.9>: Silicone elastomers for closures and tubing. 
 EP <3.2.2>: Plastic containers and closures for pharmaceutical use. 
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 ASTM F748-98: Standard Practice for Selecting Generic Biological Test Methods for 
Materials and Devices. 
1.4.2.  Connectors 
Many of the advantages of disposable technologies would be lost if manufactures could 
not safely connect systems to create an aseptic process, once a connector can be the 
determining factor in keeping a process strictly aseptic (Boehm, J., 2010). 
The risk of contamination requires special attention in biopharmaceutical processes since 
almost every biopharmaceutical process implicates making sterile connections between 
fluid pathways. Traditionally, reusable fittings have been used, particularly those made 
of stainless steel (e.g. a stainless steel tri-clamp), but the tendency is towards the use of 
disposable connectors (Mach, C. J., & Riedman, D., 2008). 
A wide variety of connectors are commercially available and the right choice depends on 
the needs and preferences of a given facility and customer (Boehm, J., 2010). 
The different types of connectors are summarized in the table below (Rothe, S. & Eibl 
D., 2011; Niazi, S. K., 2012; Shukla, A., Mostafa, S., Wilson, M., & Lange, D., 2012): 
 
 
 
 
 
 
 
 
 
 
 
 
Table 10. Different types of connectors. Adapted from Rothe, S. & Eibl D. (2011), Niazi, S. 
K. (2012), Shukla, A., Mostafa, S., Wilson, M., & Lange, D. (2012). 
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There are different systems for aseptic connection: 
1. Connection under laminar flow hood or in a clean room area class A: 
Luer-lock connectors, tri-clamps and quick (dis)connect connectors provide fast and easy 
connections and should be used together with laminar flow hood. Careful handling with 
this type of connectors is needed to prevent contamination. Examples of this kind of 
connectors are: tri-clamps and MPC® Series from Colder Company (Boehm, J., 2010; 
Rothe, S. & Eibl D., 2011). 
 
 
 
 
 
 
2. Sterilisation in place connectors: 
These types of connectors create sterile connections between a range of disposable 
systems and stainless steel equipment. They can be sterilized at the point of connection. 
Examples of this kind of connectors are: Steam-Thru System® from Colder Company and 
Lynx ST® from Millipore Company (Boehm, J., 2010; Rothe, S. & Eibl D., 2011). 
 
 
 
 
 
 
3. Aseptic connectors 
Aseptic connectors allow aseptic connection without laminar flow hood like conventional 
connectors. These connectors are secure, the connections can be achieved rapidly without 
any further support or additional equipment and permit a sterile fluid pathway in a non-
Figure 4. Quick-connectors: MPC® 
Series from Colder Company 
Figure 6. Lynx ST® from 
Millipore Company 
a) b) 
Figure 3. Triclamp disposable (a) and a 
stainless steel clamp (b) 
Figure 5. Steam-Thru System® 
from Colder Company 
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aseptic environment (gray space). The aseptic parts on the connector side are sealed with 
sterile membrane filters or caps. After coupling, the sterile membrane filters or caps must 
be removed and both parts have to be clamped or fixed. The connection is then ready for 
use. It is not possible to disconnect connectors that are once connected. Examples of this 
kind of connectors are: Kleenpak KPC® by Pall, Lynx S2S® by Millipore, Opta SFT-1® 
by Sartorius Stedim Biotech, ReadyMate DAC® by GE and the Pure-Fit SC® by Saint-
Gobain (Strahlendorf, K. A., & Harper, K., 2009; Boehm, J., 2010; Rothe, S. & Eibl D., 
2011). 
 
 
 
 
 
 
 
 
 
 
 
The variety of plastics and connectors enables the development of innovative equipment 
and provides customization. 
 
 
 
Figure 9. Opta SFT-1® by Sartorius 
Stedim Biotech 
Figure 11. Pure-Fit SC® by 
Saint-Gobain 
Figure 8. Lynx S2S® by Millipore 
Figure 10. ReadyMate DAC® by 
GE 
Figure 7. Kleenpak KPC® by Pall 
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1.5.  Fluid transfer 
In the manufacturing process the fluid can be transferred either by pump systems or by 
pressurizing (Kubischik, J. & Schaupp, M., 2011). 
1.5.1.  Pump systems 
Pumps can be classified in two types: positive displacement pumps and rotodynamic 
pumps. Both types are designed to transfer fluids but the way this is accomplished differs 
(Srinivasan, K. M., 2008).  
 
 
 
 
 
 
 
 
 
 
A positive displacement pump moves the same amount of fluid for each rotating cycle of 
the system. It uses mechanisms that seals fluid in a chamber and forces it out by reducing 
the volume of the chamber. This action increases the fluid pressure. The motion can be 
rotary or reciprocating (Srinivasan, K. M., 2008; Gupta, A. K. & Arora, S. K., 2013).  
In a rotodynamic pump there is a free passage of fluid between the inlet and outlet of the 
machine without sealing. Rotodynamic pumps have a rotating part called impeller, which 
rotates the fluid continuously and transfers energy from the rotor to the fluid (Garde, R. 
J., 1997; Gupta, A. K. & Arora, S. K., 2013). 
Piston pumps have been a traditional technology in pharmaceutical technology. However 
due to stricter validation requirements and design innovations peristaltic pumps started to 
be considered instead of piston pumps (Lambert, P., (2008). 
 
Figure 12. Classification of pumps. Adapted from Srinivasan, K. M. (2008). 
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Piston pump 
A piston pump is a positive displacement pump. It is a mechanical device that cycles 
through a suction phase and a pressure phase to move fluid. Internal parts of a piston 
pump (gaskets, seals, valves and internal surfaces) are in direct contact with the fluid. 
Piston pumps are known for their reliability and accuracy. However, they require regular 
maintenance and disassembly for cleaning and sterilization and cross contamination 
between batches is a concern. In addition, they also apply high pressure and high shear 
forces, that are inappropriate for biological drugs which are shear sensitive (Lambert, P., 
2008).  
Peristaltic pump 
A peristaltic pump is also a positive displacement pump. In this pump type the fluid is 
moved forward by progressively squeezing and releasing the flexible tubing (Avis, K. E. 
(Ed.) 1995; Lipták, B. G. (Ed), 2003; Volk, M., 2014). The product only comes in contact 
with the flexible tubing. For this reason peristaltic pumps can be used for single aseptic 
processes (Lambert, P., 2008).  
Peristaltic pumps using disposable tubes eliminate the possibility of cross contamination 
and the cleaning of the pump isn't required since the tubing is the only part that comes 
into contact with the fluid (Lipták, B. G. (Ed), 2003; Niazi, S. K., 2012). It also can be 
used with some biological drugs that are shear sensitive, since they apply low pressure 
and provide a gentle handling (Niazi, S. K., 2012).  However, studies have shown that 
some tubing materials release particles (spalling) during the use with peristaltic pumps, 
due to their poor abrasion resistance and consequently, contaminating the solution (Bahal, 
S. M., & Romansky, J. M., 2002; Colas, A., Malczewski, R., & Ulman, K., 2004).  
1.5.2.  Pressurizing 
Fluids can be transferred by using pressurized gas or vacuum, when pumps are not 
available, when their use might cause contamination or degradation due to mechanical 
shear or when handling abrasive or corrosive materials, thus avoiding pumping the 
materials. Pressurized systems use nitrogen, air or other gas under moderate to high 
pressure to force the transfer of the fluid (CCPS, 1993; Kerry, F. G., 2007). 
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1.6.  Influence of Pump systems and Pressurizing in protein solutions 
In some cases, during manufacturing, proteins undergo a variety of stresses leading to 
physical and chemical instability that can compromise the quality, safety and efficiency 
of the proteins, such as monoclonal antibodies and the yield of the final drug product. 
Physical instability causes changes in the higher order structure of proteins (secondary, 
tertiary or quaternary structure), which include denaturation, aggregation, precipitation or 
adsorption to surfaces. Chemical instability is a covalent modification of the protein via 
bond formation or cleavage (Banga, A. K., 2005; Bausch, U. J., 2008; Vázquez-Rey, M., 
& Lang, D. A., 2011; Ma, J. K., & Hadzija, B., 2013). 
Protein aggregation can be induced by various processing steps during manufacture such 
as pumping and pressurization (Vázquez-Rey, M., & Lang, D. A., 2011).  
Pumping processes expose proteins to mechanical shear forces that can cause protein 
aggregation and formation of particles. However, the extent of impact depends on the 
intensity and on the duration of exposure to such stress. Shearing creates a hydrophobic 
air/water interface which results in the alignment of protein molecules at the interface. 
The alignment of the protein molecules at the interface occurs since proteins denature 
exposing the hydrophobic residues to the air, forming unfolded intermediates that induce 
protein aggregation (Wang, W., 1999; Vázquez-Rey, M., & Lang, D. A., 2011; Ma, J. K., 
& Hadzija, B., 2013). To reduce shearing-induced protein aggregation, surfactants can be 
used as they compete with the protein molecules for the hydrophobic interfaces by 
binding directly to proteins or by increasing the viscosity of a protein solution limiting 
the movement of proteins (Wang, W., Nema, S., & Teagarden, D., 2010). Certain pumps 
like piston pumps and peristaltic pumps can form protein particles (for example white 
tornadoes) due to shear. However, peristaltic pumps generate less protein particles as 
piston pumps (Bausch, U. J., 2008; Roche Internal Report, 2008; Nayak, A., Colandene, 
J., Bradford, V., & Perkins, M., 2011). 
Despite peristaltic pumps being advertised to be used with biological drugs that are shear 
sensitive, it was shown that they also can form protein aggregation and protein particles 
due to shear forces (Maggio, E. T., 2008). Some authors correlate the formation of protein 
aggregation with the material of the tubing (Thomas, C. R., & Geer, D., 2010, Vázquez-
Rey, M., & Lang, D. A., 2011). 
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The formation of aggregates due to pumping can also be minimized using pressure for 
the transfer of fluids (Vázquez-Rey, M., & Lang, D. A., 2011). 
Low to moderate pressures exert no significant effect on the aggregation of proteins. 
However, high pressure can cause protein denaturation and facilitate protein aggregation 
due to increased hydrophobic interactions. The pressure-induced protein aggregation has 
not been a major problem in the manufacturing of proteins therapeutics since the pressure 
that is required to unfold proteins must be greater than 100 MPa, which is beyond the 
range of routine exposure (Chang, B. S., & Yeung, B., 2010; Wang, W., Nema, S., & 
Teagarden, D., 2010; Meersman, F., Daniel, I., Bartlett, D. H., Winter, R., Hazael, R., & 
McMillain, P. F., 2013). 
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2. Target 
The purpose of this master thesis is to test the possibility to transfer API solutions with 
peristaltic pump and overpressure in combination with a combined thawing and transfer 
disposable tube and to verify if it is advantageous to replace the current thawing and 
transfer disposable tubes used in the API thawing and drug product compounding process 
by a new combined thawing and transfer disposable tube in order to diminish the quality 
risks of manual handling, reduce assembling time and improve safety of ADCs.  
With that purpose in mind, a series of practical experiments will be performed, which 
consist of testing three different combined thawing and transfer disposable tubes with two 
methods for moving fluid: peristaltic pump and overpressure. Testing a new combined 
disposable with overpressure and additionally, using a peristaltic pump for the transfer of 
API solution would be innovative in the methods used in Roche Diagnostics GmbH, 
Mannheim drug product compounding processes, since until today the only moving fluid 
method used for transfer has been overpressure with a specific tube with pressure 
capabilities. In addition, the transfer speeds will be calculated, the length and diameter of 
the tubes will be measured and the whole handling process evaluated in order to compare 
their benefits and disadvantages from the quality and efficiency perspective. 
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3. Types of Cryo-vessels  
Roche Diagnostics GmbH, Mannheim operates with three different types of cryo-vessels, 
namely US (United States Cryo-vessel), Basel and Penzberger (European Cryo-vessels). 
3.1.  US Cryo-vessel Type 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Two sizes of US Cryo-vessel are used: 120 L (small vessel) and 300 L (big vessel). 
 
Figure 13. US Cryo-vessel type: Filling, Thawing and Transfer processes 
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The product filling process (Process A) is the same regardless of what type of cryo-vessel 
is utilized. The filling of API solution is done by a dip tube, which extends from the top 
of the cryo-vessel to the bottom, allowing the filling of the inner compartment. After the 
filling process is completed, the cryo-vessel can be transported and stored.  
The thawing process is divided in two cycles: silicon oil and product cycle (Process B). 
Silicon oil cycle: the silicon oil circulates in the outer compartment of the cryo-vessel, 
named double coat and in the inner tube snake.  The circulation of the silicon oil in the 
cryo-vessel warms the API solution allowing its thawing.  
Product cycle: it is used a thawing disposable tube, that is connected on the bottom valve 
and on the upper valve and passes through a peristaltic pump, that pumps the API solution 
for its homogenization and for heat distribution during thawing. The API circulation starts 
always from the bottom valve to the upper valve, where it enters in the inner compartment. 
The transfer of the API solution (Process C) is made through a transfer disposable tube 
that is connected to the bottom valve and to the receiving tank in the compounding room. 
The transfer process is done through overpressure with nitrogen, where the nitrogen has 
to pass through a 0,22 µm filter in the cryo-vessel to ensure sterility (figure 13, Process 
C). 
(a) 
Figure 14. US Cryo-vessel type of (a) 120 L and (b) 300 L, with upper and bottom valves 
highlighted. 
(b) 
Bottom valves 
Upper valves 
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3.2.  Basel and Penzberger Cryo-vessel Types 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Basel and Penzberger Cryo-vessel types only exist with the capacity of 300 L. They 
differ from each other in the localization of the upper valve and the dip tube.  
 
 
 
 
 
 
 
Figure 15. Basel and Penzberger Cryo-vessel: Filling, Thawing and Transfer processes 
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The differences between US Cryo-vessel type and Basel and Penzberger Cryo-vessel 
types are in the thawing process (Process B), in the product cycle and in the transfer 
process (Process C). 
Product cycle (Process B): the thawing disposable tube is connected on the dip tube from 
where the API solution leaves, passes through a peristaltic pump, and on the upper valve 
where the API solution enters to the inner compartment.  
The transfer of the API solution (Process C) is made through a transfer disposable tube 
that is connected to the dip tube and to the receiving tank in the compounding room. With 
the Basel and Penzberger Cryo-vessel types the transfer process is also done through 
a) 
b) 
 
Figure 16. Penzberger Cryo-vessel type of 300 L 
(left) and close-up showing of the upper valve (a) 
and of the dip tube (b) 
Figure 17. Basel Cryo-vessel type of 300 L (left) and close-up showing of the upper 
valve (a) and of the dip tube (b) 
a) 
b) 
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overpressure with nitrogen where the nitrogen has to pass through a 0,22 µm filter in the 
cryo-vessel to ensure sterility (see figure 15 – Process C).  
 
 
Today’s Cryo-vessel process cycle (API), Roche Mannheim 
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4. Today’s Cryo-vessel process cycle (API), Roche Mannheim 
 
 
 
 
 
 
 
 
 
Figure 18. Today’s Cryo-vessel process cycle in Roche Diagnostics GmbH, Mannheim 
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5. Today’s API thawing and transfer process 
Before starting the thawing process the thawing disposable tube must be attached to the 
cryo-vessel in a class C room. The thawing disposable tube length is approximately 4 
meters (m) and must be cut with a sterilized scissor in two parts, one with the length of 
approximately 3 m and the other with the length of approximately 1 m. Linked to the 
thawing tube is a Nova Septum® bag for bioburden sampling and a syringe used for 
endotoxins (LAL test) sampling. The polyethylene Nova Septum® bag was validated for 
bioburden and the polycarbonate syringe was validated for endotoxins (Roche Internal 
Document, 2010). 
In a 2-8 °C room the thawing tube is connected to a peristaltic pump, which will allow 
the thawing process, product cycle. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 19. Today’s thawing tube (a) attached with a Nova Septum® and a syringe for 
sampling (b) 
(a) 
(b) 
(b) 
Figure 20. Upper valve of US Cryo-vessel (a) and connection of the thawing disposable tube with the upper 
valve before the thawing process (b) 
(a) (b) 
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Subsequently, begins the silicon oil cycle. The silicon oil circulates in the outer 
compartment of the cryo-vessel, named double coat and in the inner tube snake, heating 
the API solution. 
 
(a) (b) 
Table 12. Features of the today’s transfer tube material. Adapted from 
AdvantaPure (2012). 
Table 11. Today’s Tube features 
Figure 21. Bottom valve of US Cryo-vessel (a) and connection of the thawing disposable tube with the 
bottom valve before the thawing process (b) 
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After four hours of heating starts the product circulation via peristaltic pump. The thawing 
process takes 9 hours in case of a small cryo-vessel (120 L) and 12 hours in case of a big 
cryo-vessel (300 L). 
 
 
 
 
 
 
 
 
During the thawing process the operators and a machine document the thawing 
parameters (GMP-batch record). After the thawing process the cryo-vessel is cleaned 
outside and transported to a C-room. There, the operators take samples for 
microbiological Quality Control (QC) analysis of bioburden (Nova Septum® bag) and 
endotoxins, due to a LAL test (syringe) and take a sample for chemical QC analysis of 
identity of the API solution. The batch record, the analysis of bioburden and endotoxins 
and the analysis of identity will be reviewed by the QC. After that, the QC makes the 
decision to release, reject or quarantine the cryo-vessel in accordance with the quality.  
Figure 23. Peristaltic pump for product circulation and the today´s thawing 
disposable tube in the peristaltic pump for product circulation 
Figure 22. The silicon oil cycle. (a) Entry of silicon oil in the cryo-vessel; (b) Circulation of 
silicon oil in the double coat and in the inner tube snake in the cryo-vessel; (c) Exit of silicon 
oil out of the cryo-vessel 
(a) (b) (c) 
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Subsequently they remove the thawing disposable tube and connect an adapter on the 
bottom valve in case of a US cryo-vessel. Before the implementation of an adapter, the 
operators in the compounding room had to lie down on the floor to connect the transfer 
tube with the compounding tank which increased the contamination risks. Therefore, the 
implementation of an adapter on the bottom valve aims to avoid having to lie down on 
the floor to connect the transfer tube from the cryo-vessel to the compounding tank. 
Consequently the adapter enables a safer connection between the cryo-vessel and the 
compounding tank and prevents operators from lying down on the floor minimizing the 
contamination risks. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. Operators lying on the floor to connect the transfer tube before implementation of the adapter 
Figure 25. Adapter used for the today’s connection of 
the transfer tube with the US Cryo-vessel 
Figure 26. Operators doing the connection of the transfer tube after implementation of the adapter 
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When the QC decides that the microbiological and chemical samples and that the batch 
record meet the specifications, the cryo-vessel can be released.  
In the compounding room, before connecting the transfer disposable tube from the cryo-
vessel to the compounding tank the operators must to do a quick LAL test (Diagnostic 
Kit) for some products to check the microbiological quality after holding time 
(approximately two weeks). Sometimes it is necessary to use more than one cryo-vessel 
for the compounding. Therefore, the LAL test is made to prevent financial risks due to 
the possibility of the mixture of one API solution with suboptimal quality from one cryo-
vessel with one with optimal quality from another cryo-vessel. If the result of the quick 
LAL test is negative they can connect the transfer disposable tube to the adapter in the 
cryo-vessel to and to the compounding tank and start the transfer process. The API 
solution is transferred trough overpressure to the compounding tank. 
 
 
 
 
 
 
 
 
With this master work a first data base will be created for the decision if Roche 
Diagnostics GmbH, Mannheim can adopt a combined thawing and transfer disposable 
tube to reduce the operators manipulation and the assembly time. Moreover, with the 
implementation of a combined thawing and transfer disposable tube the operators will no 
longer need to connect an adapter on the bottom valve. Additionally it can be used with 
highly potent drugs (ADCs).  
 
Figure 27. Today’s transfer disposable tube 
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6. Materials and Methods 
The possibility of transferring product with a peristaltic pump and with overpressure in 
combination with a combined thawing and transfer disposable tube was tested and the 
most suitable method verified. Additionally, the transfer speed (kg/min) of three different 
combined thawing and transfer disposable tubes (Tube A, B and C) was measured using 
both transfer fluid methods, peristaltic pump and overpressure, and compared with the 
transfer speed of today´s transfer with overpressure of Product A, taking also into account 
other additional factors as presented in the tables 11 and 13. 
Tube A is the only combined thawing and transfer disposable tube that is already qualified 
according to the cGMP.  
Tube B and C were specially designed for Roche Diagnostics GmbH, Mannheim. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 13. Combined thawing and transfer Tubes A, B and C features. 
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The experiments were performed on the pharmaceutical GMP equipment of Roche 
Diagnostics GmbH, Mannheim in the compounding room of Module 1 (pharmaceutical 
sterile drug product manufacturing process). The experiments were not performed under 
GMP conditions; for that reason the combined thawing and transfer disposable tubes were 
connected in a class D room.  
Since Roche Diagnostics GmbH, Mannheim only works in a GMP environment the use 
of all types of cryo-vessels that were explained was not possible. In order to use a cryo-
vessel for experiments, cleaning validation is needed due to possible API residues. The 
only cryo-vessel that was available to make the experiments was a US Cryo-vessel type 
(300 L), as it is a GMP training test vessel. 
Figure 28. Peristaltic pump (up) and 
manometer and overpressure tube (right) used 
in the experiment 
Table 14. Features of the tube materials used in the experiment. Adapted from Dow 
Corning and Saint-Gobain (2014). 
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The solution that was used for testing was water for injection (WFI). For each designed 
experiment with the exception of the experiment with Tube C (pressure) the cryo-vessel 
was filled four times with WFI to obtain a final amount of 1031 kg of transfer solution. 
For the experiment with Tube C with pressure the cryo-vessel was filled three times with 
WFI to obtain a final amount of 1031 kg of transfer solution. 
 
 
 
 
 
 
Amount of transfer product 
The maximum volume that can be transferred to the compounding tank is approximately 
1050 L. The compounding tank measures the transfer product in kg. So when the transfer 
product is WFI and 1000 L of WFI should be transferred, the final amount in the 
compounding tank is 1000 kg since the density of water is approximately 1g/cm3.  
𝐷𝑒𝑛𝑠𝑖𝑡𝑦 (𝑔 𝑐𝑚3)⁄ =  
𝐴𝑚𝑜𝑢𝑛𝑡 (𝑔)
𝑉𝑜𝑙𝑢𝑚𝑒 (𝑐𝑚3)
  =  
𝐴𝑚𝑜𝑢𝑛𝑡 (𝑘𝑔)
𝑉𝑜𝑙𝑢𝑚𝑒 (𝑑𝑚3)
=
𝐴𝑚𝑜𝑢𝑛𝑡 (𝑘𝑔)
𝑉𝑜𝑙𝑢𝑚𝑒 (𝐿)
 
 
⇔ 
 
⇔  𝐴𝑚𝑜𝑢𝑛𝑡 (𝑘𝑔) = 𝐷𝑒𝑛𝑠𝑖𝑡𝑦 (𝑔 𝑐𝑚3⁄ ) x 𝑉𝑜𝑙𝑢𝑚𝑒 (𝐿)  
 
⇔ 
 
⇔           𝐴𝑚𝑜𝑢𝑛𝑡 = 1 x 1000 = 1000 𝑘𝑔 
Figure 29. US Cryo-vessel (300 L) used in the experiment 
Figure 30. Filling the US Cryo-
vessel with WFI 
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However Product A, which is used for the comparing of the transfer process, has a 
density of approximately 1,031g/cm3 which means that the final amount of transferred 
product in the compounding tank is 1031 kg. 
 𝐴𝑚𝑜𝑢𝑛𝑡 (𝑘𝑔) = 𝐷𝑒𝑛𝑠𝑖𝑡𝑦 (𝑔 𝑐𝑚3⁄ ) x 𝑉𝑜𝑙𝑢𝑚𝑒 (𝐿)  
 
⇔ 
 
⇔           𝐴𝑚𝑜𝑢𝑛𝑡 = 1,031 x 1000 =  1031 𝑘𝑔                                               
Since the final amount of the transferred product of Product A is 1031 kg it was 
transferred 1031 kg of WFI so that a comparison of the transfer speeds is possible.  
6.1. Experiment 
6.1.1. Tube A. 
The first combined thawing and transfer disposable tube that was tested was Tube A. This 
tube is only suitable for the use of non-highly potent drugs and consists of three parts. 
Part A and B are intended to connect to the cryo-vessel for the thawing process and Part 
C combined with a Lynx S2S® connector is intended to connect to the compounding tank 
for the transfer process. Coupled to Part A are Nova Septum® bags that serve for batch 
sampling (Part D) (see figure 31). 
 
 
 
 
 
 
 
 
 
 
 
Part C 
with Lynx 
S2S 
Part D 
Figure 31. First disposable tube that was tested - Tube A. Part A is 
intended to connect with the upper valve, part B is intended to connect 
with the bottom valve, part C is intended to connect with the 
compounding tank and part D is intended to take samples 
Part A 
Part B 
Part D Part C with 
Lynx S2S 
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Tube A was connected to the cryo-vessel in a class D room and then transported to the 
compounding room, class C room. Part A was connected to the upper valve of the cryo-
vessel with a metal clamp and part B was connected to the bottom valve of the cryo-vessel 
also with a metal clamp.  
 
 
 
 
 
 
 
 
Two methods were used as moving force for the transfer of the solution to the 
compounding tank: peristaltic pump and overpressure. 
Experiment with peristaltic pump:  
Although Part C has a Lynx S2S® connector, the experiment wasn´t performed with it as 
it was designed for another plant and didn´t fit for Module 1 processes. Therefore, the 
operators cut the connector and connected a short tube with a tri-clamp connection to the 
existing tube. In the compounding room the transfer tube (Part C) was connected to the 
compounding tank passing through a peristaltic pump with a tube connection piece. For 
the transfer process approximately 200 rpm were used. 
 
 
 
 
 
 
 
Figure 32. US Cryo-vessel with Tube A in class D room 
(a) (b) 
Figure 33. Part C of tube A with Lynx S2S® connector and with a tube connection piece (a) and 
Part C of Tube A after removing the Lynx S2S® connector and with a tube connection piece (b) 
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Experiment with overpressure: 
In the compounding room the transfer tube without Lynx S2S® connector (Part C) was 
connected to the compounding tank with a tube connection piece. Afterwards, the 
overpressure tube (nitrogen) was connected to the cryo-vessel. For the transfer process 
approximately 0,5 bar was used. Before nitrogen enters into the cryo-vessel it has to pass 
a 0,22 µm filter to ensure sterility.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34. Part C of Tube A passing through the peristaltic pump 
(a) 
(b) 
(c) 
Figure 35. Manometer (a), overpressure tube (blue tube) (b) and overpressure tube connected to the 
US Cryo-vessel in class C-room (c) 
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Experiment design of Tube A with peristaltic pump and overpressure: 
 
 
 
 
 
 
 
 
6.1.2. Tube B. 
The second tube that was tested was Tube B. This tube is a delivery tube for the 
connection of different cryo-vessels (y-connector). It can connect up to four different 
cryo-vessels (Part B, C, D and E) and can be used for the handling of API solutions and 
for highly potent drugs, ADCs. Part A is intended for the connection with the 
compounding tank and Part F is intended for flushing in case of highly potent drugs, 
ADCs manipulation allowing the cleaning of the tube. However, Tube B was tested as a 
combined thawing and transfer disposable tube to test the silicon tube material (see figure 
37). 
 
 
 
 
 
 
 
 
Part C 
Part D 
Part E 
Part B 
Part A 
Part F 
Figure 37. Second disposable tube that was tested - Tube B. Part A is intended to connect with the 
compounding tank, Part B, C, D, E are intended to connect with different cryo-vessels and part F is 
intended for flushing 
Figure 36. Experiment design of Tube A (a) with peristaltic pump and (b) with overpressure 
(a) (b) 
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Tube B was connected to the cryo-vessel in a class D room and then transported to the 
compounding room, class C room. Part A was connected to the upper valve with a tri-
clamp connection and part C was connected to the bottom valve of the cryo-vessel also 
with a tri-clamp connection.  
 
 
 
    
 
 
 
 
Two methods were used as moving force for the transfer of the solution to the 
compounding tank: peristaltic pump and overpressure. 
Experiment with peristaltic pump:  
In the compounding room the transfer tube (Part E) was connected to the compounding 
tank with a tri-clamp connection passing through a peristaltic pump. For the transfer 
process approximately 200 rpm was used. 
 
 
 
 
 
 
 
 
 
Figure 39. Part E of Tube B passing 
through the peristaltic pump 
Figure 38. US Cryo-vessel with 
Tube B in class D room 
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Experiment with overpressure: 
In the compounding room the transfer tube (Part E) was connected to the compounding 
tank with a tri-clamp connection. Afterwards, the overpressure tube (nitrogen) was 
connected to the cryo-vessel. For the transfer process approximately 0,5 bar was used. 
Before nitrogen enters into the cryo-vessel it has to pass a 0,22 µm filter to assure sterility. 
 
 
 
 
 
 
 
 
 
 
Experiment design of Tube B with peristaltic pump and overpressure: 
 
 
 
 
 
 
 
 
 
 
Figure 40. Manometer (a) and overpressure tube 
(blue tube) (b) and overpressure tube connected to 
the US Cryo-vessel in class C-room (c) 
(a) 
(b) 
(c) 
Figure 41. Experiment design of Tube B (a) with peristaltic pump and (b) with 
overpressure 
(a) (b) 
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6.1.3. Tube C. 
The third combined thawing and transfer tube that was tested was Tube C. This tube is 
designed for using with API solutions and ADCs. Part A and B are intended to connect 
with the cryo-vessel with a tri-clamp connection for the thawing process. After the 
thawing process it is also possible to take batch samples with Part E.  Part E is composed 
of a Nova Septum® bag for bioburden sampling and a syringe for endotoxin sampling. 
Connected to part A and B is Part D. Part D is designed for flushing when handling with 
highly potent drugs, ADCs, allowing the cleaning of the tube. Part C is used for the 
transfer process (see figure 42).  
This combined disposable tube was designed to allow the connection of Part C with the 
y-connector (Tube B) and this one with the compounding tank. This concept was intended 
for highly potent drugs, ADCs. 
 
 
 
 
 
 
 
 
 
 
 
Tube C was connected to the cryo-vessel in a class D room and then transported to the 
compounding room, class C room. Part A was connected to the upper valve of the cryo-
vessel with a tri-clamp connection and part B was connected to the bottom valve of the 
cryo-vessel also with a tri-clamp connection.  
 
 
Part B 
Part C 
Part D 
Part E 
Part C 
Figure 42. Third disposable tube that was tested - Tube C. Part A is intended to connect with 
the upper valve, part B is intended to connect with the bottom valve, part C is intended to 
connect with the compounding tank and part D is intended for flushing.  
Part A 
Part D 
Part D 
Part B 
Part E 
Part C 
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Two methods were used as moving force for the transfer of the solution to the 
compounding tank: peristaltic pump and overpressure. 
 
Figure 44. Transfer concept for ADCs: connection 
of Tube C with y-connector and connection of y-
connector with the compounding tank 
Figure 43. US Cryo-vessel with Tube C in class D room (a) and US Cryo-vessel with Tube C connected 
to the y-connector in class D room (b) 
(a) (b) 
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Experiment with peristaltic pump:  
In the compounding room the transfer tube (Part C) was connected to the y-connector 
with a tri-clamp connection passing through a peristaltic pump. The y-connector was 
connected to the compounding tank with a tri-clamp connection. For the transfer process 
approximately 200 rpm was used. 
 
 
 
 
 
 
 
 
Experiment with overpressure: 
In the compounding room the transfer tube (Part C) was connected to the y-connector 
with a tri-clamp connection. Then the y-connector was connected to the compounding 
tank as well with a tri-clamp connection. Subsequently, the pressure tube (nitrogen) was 
connected to the cryo-vessel. For the transfer process approximately 0,5 bar was used. 
Before nitrogen enters into the cryo-vessel it has to pass a 0,22 µm filter to assure sterility.  
 
 
 
 
 
 
 
Figure 46. Manometer (a), overpressure tube (blue tube) (b) and overpressure tube connected to the 
Cryo-vessel in class C-room (c) 
(a) 
(b) 
(c) 
Figure 45. Part D of y connector 
(connected to Tube C) passing through the 
peristaltic pump 
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Experiment design of Tube C with peristaltic pump and overpressure: 
 
 
 
 
 
 
 
 
 
 
Figure 47. Experiment design of Tube C with (a) peristaltic pump and (b) overpressure 
(a) (b) 
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7. Results 
The possibility to transfer product with a peristaltic pump and with overpressure in 
combination with a combined thawing and transfer disposable tube as well as the most 
suitable transfer method were tested. Additionally, the transfer speeds of three combined 
thawing and transfer disposable tubes (Tube A, B and C) in combination with the two 
transfer methods were measured to see if it is advantageous to replace the current thawing 
and transfer disposable tubes by a new combined thawing and transfer disposable tube 
from the point of view of speed/time efficiency. The results are summarized on the table 
below, which also presents data regarding to the transfer speed from product A with the 
today´s transfer disposable tube. It is important to mention that the today´s disposable 
tube only has results for overpressure, since nowadays this is the only method used for 
the transfer of the product to the compounding tank in Module 1, Mannheim. 
 
 
 
 
 
 
 
 
The table shows that it is possible to transfer product with both methods: peristaltic pump 
and overpressure. 
Moreover, according to the table it can also be seen that the today´s transfer tube needs 
102 minutes (min) to transfer an amount of 1031 kg with overpressure.  
Tube A could transfer an amount of 1031 kg through the peristaltic pump in 166 min and 
an amount of 1031 kg with overpressure in 115 min. 
Tube B could transfer an amount of 1031 kg through the peristaltic pump in 113 min and 
an amount of 1031 kg with overpressure in 85 min.  
Table 15. Transfer speeds of Today´s Tube and Tube A, B and C 
Transferred 
amount (kg)
Transfer time 
(min)
Transferred 
amount (kg)
Transfer time 
(min)
Transferred 
amount (kg)
Transfer time 
(min)
Transferred 
amount (kg)
Transfer time 
(min)
Refill 1 280 42 290 31 310 46
Refill 2 640 95 560 63 610 91
Refill 3 914 139 850 94 910 135
Refill 4 1031 166 1031 113 1031 151
Refill 1 310 31 310 33 310 25 360 35
Refill 2 610 59 610 65 640 53 710 75
Refill 3 910 88 910 100 910 75
Refill 4 1031 102 1031 115 1031 85 1031 114
Transfer speed 
Methods Cryovessel
Tubes
Today's Tube Tube A Tube B Tube C
Product A WFI WFI WFI
Peristaltic 
pump
(≈ 200 rpm)
Overpressure 
N2 
(≈ 0,5 bar)
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At last, one can also observe that Tube C could transfer an amount of 1031 kg through 
the peristaltic pump in 151 min and an amount of 1031 kg with overpressure in 114 min.  
Consequently one can say that the transfer method with overpressure is faster than the 
transfer method with peristaltic pump. 
To summarize, Tube B reveals a better transfer speed with peristaltic pump and with 
overpressure. 
Based on the above results it is possible to design three graphs. The first one compares 
the transfer speeds between the tubes with peristaltic pump, the second one compares the 
transfer speeds with overpressure and the third one compares the transfer speeds between 
the tubes with peristaltic pump and overpressure. 
On the y axis the amounts of transferred product are expressed in kilograms, while on the 
x axis the time of transfer is represented in minutes. The transfer speeds are represented 
by plotted lines that combine the accumulated time (in minutes) and the transferred 
amounts to accumulate 1031 kg of product. 
 
 
 
 
 
 
 
 
Tube B reveals a better transfer speed with peristaltic pump. 
 
 
 
 
 
Figure 48. Transfer speed of the tubes with peristaltic pump 
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Tube B also reveals a better transfer speed with overpressure. 
 
 
 
 
 
 
 
 
 
The transfer speed of the tubes using the overpressure method is in each single subgroup 
higher than the one using the peristaltic pump method. 
To see any possible statistical significance some statistical methods were used with 
Microsoft Excel 2010 and Minitab® Software Version 16. Some statistical measures and 
analysis are presented for a better understanding of the results. Aiming to enhance the 
presentation of the results the following scheme will be considered (Brook, Q., 2010): 
 
 
 
Figure 49. Transfer speed of the tubes with overpressure 
Figure 50. Transfer speed of the tubes with peristaltic pump and overpressure 
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The same results are presented with an additional column in the following table showing 
the transferred amount/time in each refill for each tube according to the two transfer 
methods (peristaltic pump and overpressure). 
𝑇𝑟𝑎𝑛𝑓𝑒𝑟𝑟𝑒𝑑 𝑎𝑚𝑜𝑢𝑛𝑡 𝑡𝑖𝑚𝑒⁄ =
𝑇𝑟𝑎𝑛𝑠𝑓𝑒𝑟𝑟𝑒𝑑 𝑎𝑚𝑜𝑢𝑛𝑡 (𝑘𝑔)
𝑇𝑟𝑎𝑛𝑠𝑓𝑒𝑟 𝑡𝑖𝑚𝑒 (𝑚𝑖𝑛)
 
 
 
 
 
 
 
 
Figure 51. Overview of some statistical analysis. Adapted from Brook, Q. (2010). 
Table 16. Transferred amount/time of Today´s tube, Tube A, B and C 
Transferred amount
 (kg)
Transfer time
 (min)
Transferred amount/time
 (Kg/min)
Transferred amount
 (kg)
Transfer time 
(min)
Transferred amount/time
 (Kg/min)
310 31 10
610 59 10,34
910 88 10,34
1031 102 10,11
280 42 6,67 310 33 9,39
640 95 6,74 610 65 9,38
914 139 6,58 910 100 9,10
1031 166 6,21 1031 115 8,97
290 31 9,35 310 25 12,40
560 63 8,89 640 53 12,08
850 94 9,04 910 75 12,13
1031 113 9,12 1031 85 12,13
310 46 6,74 360 35 10,29
610 91 6,70 710 75 9,47
910 135 6,74
1031 151 6,83 1031 114 9,04
Pressure
Tube 1
(Today´s 
tube)
Tube 2
 (Tube A)
Tube 3
(Tube B)
Tube 4
 (Tube C)
Tubes
Pump
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Table 17. Correspondence of the tubes for the 
statistical methods 
Given the reduced number of measured data points the statistical results should be 
analysed with caution. However, to better understand the data the following tools were 
used.  
 
 
 
 
 
Overview of measures 
Descriptive statistics 
 
 
 
 
 
 
 
 
 
 
 
The statistical results reveal a transferred amount/time near to the mean value of the 
different refills, thus verifying low standard deviations of the results in all of the tested 
tubes with the two transfer methods. 
The maximum and minimum values and the median for the results of the different tests 
were calculated for a better understanding of the data characteristics. 
 
Descriptive Statistics: Pump transferred amount/time; Pressure transferred amount 
/time 
Figure 52. Descriptive Statistics: Transferred amount/time with 
peristaltic pump and transferred amount /time with overpressure 
Results 
71 
Graphical representation  
 
 
 
 
 
 
 
 
The graph represents the transferred amount/time in the different refills for the tested 
tubes according to the two transfer methods. 
Numeric data used for measuring 
The data obtained for the transfer amount/min are continuous data since they assume 
values over the entire measured period and are clearly not limited to whole numbers. The 
continuous data sometimes follow a normal distribution (Pedroso, A. C. & Gama, S. M. 
A., 2004; Brook, Q., 2010). 
Process behaviour 
To evaluate the process behaviour of the data, a probability plot was constructed for the 
today´s tube and the tested tubes (Tube A, B and C) with the two transfer methods 
(peristaltic pump and overpressure).  
The probability plot will help to answer if the data follow a normal distribution. If it is 
the case they will fall in a straight line. However the line will never be perfectly straight 
and that is the reason for a 95% CI (confidence interval) limits on the diagram. Then if 
all points fall within the lines the data are normally distributed (Brook, Q., 2010).  
 
 
 
 
Figure 53. Transferred amount/time of the tubes with peristaltic pump and overpressure 
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As shown in the probability plot all data fall within the lines and moreover all p-values 
are greater than 0,05. Consequently the data within each subgroup follow a normal 
distribution.  
Analysis One Way ANOVA 
Since the data follow a normal distribution and the number of samples is more than three 
a One Way ANOVA was performed to compare the means of the data samples and decide 
if they are statistically different.  
For the One Way ANOVA technique there are two hypothesis: the null hypothesis and 
the alternative hypothesis. The null hypothesis tests that there is no difference in the 
means of the transferred amount/time values across the four different tubes-subgroups 
with peristaltic pump and overpressure. The alternative hypothesis tests that there is a 
difference. 
Two Interval plots were calculated to compare the transferred amount/time of the 
different tubes with the two transfer methods. An interval plot is a graphical summary of 
the distribution of the samples that shows the samples central tendency and variability. 
Each dot represents a sample mean from a subgroup and each interval is a 95% CI for 
that sample mean (Pedroso, A. C. & Gama, S. M. A., 2004; Brook, Q., 2010). 
 
Probability Plot of Pump transferred amount/time; Pressure transferred amount/time 
Normal – 95% CI 
Figure 54. Probability plot of the transferred amount/time with peristaltic pump and overpressure 
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This plot compares the transferred amount/time of Tube A, B and C with peristaltic pump. 
The means seem to be different in the three tubes-subgroups but the difference between 
Tube A (thawing tube 2) and C (thawing tube 4) is probably not significant because the 
interval bars easily overlap. However, the difference between the means of Tube A 
(thawing tube 2) and C (thawing tube 4) with Tube B (thawing tube 3) is probably 
significant because the interval bars do not overlap. 
 
 
 
 
 
 
 
 
This plot compares the transferred amount/time of Today´s tube, Tube A, B and C with 
overpressure. The means seem to be different in the four tubes-subgroups but the 
difference between Today´s tube (thawing tube 1) and Tube C (thawing tube 4) and the 
difference between Tube A (thawing tube 2) and Tube C (thawing tube 4) are probably 
not significant because the interval bars easily overlap. However, in this plot it can also 
be seen that the difference between the means of Today´s tube (thawing tube 1), Tube A 
(thawing tube2) and C (thawing tube 4) with Tube B (thawing tube 3) and the difference 
Interval Plot of Pump transferred amount/time 
95% CI for the mean 
Figure 55. Interval plot for the transferred amount/time of the tubes with peristaltic pump 
Interval Plot of Pressure transferred amount/time 
95% CI for the mean 
Figure 56. Interval plot for the transferred amount/time of the tubes with overpressure 
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between Today´s tube (thawing tube 1) with Tube A (thawing tube 2) are probably 
significant because the interval bars do not overlap. 
Since the p-value is greater than 0,05 for every sample (see figure 54) the data are all 
normally distributed. As represented in table 16 the number of samples is more than three 
so a One Way ANOVA test will be performed to compare the averages of the data samples 
to decide if they are statistically different.  
The results of the ANOVA test can be presented in the ANOVA tables output (see figure 
57 and 58). 
 
 
 
 
 
 
 
 
The p-value on the ANOVA table output is the result for the hypothesis test. The p-value 
is 0, 000 which demonstrates that there is a difference in the means of the transferred 
amount/time values between the tubes-subgroups tested with the peristaltic pump method. 
In the ANOVA table output a diagram of the samples means and their 95% CI is also 
presented. Tube B (thawing tube 3) is the sample with the average value that is most 
different from the others, so maybe the results of this tube have caused the p-value of the 
whole test to be 0,000. Consequently the null hypothesis should be rejected. 
 
 
 
 
 
Figure 57. One Way ANOVA table output for the 
transferred amount/time using peristaltic pump 
One-way ANOVA: Pump transferred amount/time vs Tubes 
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In this case the p-value is also 0, 000, which demonstrates that there is a difference in the 
means of the transferred amount/time values between the tubes tested with the 
overpressure method. 
In the ANOVA table output it can be seen that Tube B (thawing tube 3) is again the 
sample with the average value most different from the others, so maybe the results of this 
tube have caused the p-value of the whole test to be 0,000. Consequently the null 
hypothesis should be rejected.  
 
Figure 58. One Way ANOVA table output for the 
transferred amount/time using overpressure 
One-way ANOVA: Pressure transferred amount/time vs Tubes 
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8. Discussion 
In the present master thesis the possibility to transfer API solutions with a peristaltic pump 
and with overpressure in combination with a combined thawing and transfer disposable 
tube were tested, with the goal of finding the most suitable method. Moreover, the transfer 
speed of three combined thawing and transfer disposable tubes was measured to decide 
if it is advantageous to replace the current single thawing and single transfer disposable 
tubes, taking also into account other additional factors. 
The results demonstrate that is possible to transfer a solution with a peristaltic pump and 
overpressure. On the one hand this was expected since the tubes that were tested are made 
of silicone which is suitable for pumps. On the other hand the tubes and connectors didn´t 
bust when overpressure was applied which means that the transfer process can also be 
done with this kind of tubes and connectors applying an overpressure of around 0,5 bar.  
The three tested combined thawing and transfer tubes reveal different results for the 
transfer speed depending on their diameter and on the length of the transfer way. The 
results demonstrate that tube B (thawing tube 3) has a faster transfer speed in both 
methods used. Additionally the ANOVA tests showed a statistical difference in relation 
to the other tubes. Considering that the flow of what was transferred corresponds to a 
laminar flow then it is possible to use the Poiseuille’s equation (it was not calculated if 
the flow was laminar or turbulent as this is not one of the targets of this master thesis): 
𝑄 =
∆𝑃 ∙ 𝜋 ∙ 𝑅4
8 ∙ 𝜂 ∙ 𝐿
 
where  
𝑄 is the volumetric flow; 
ΔP is the pressure difference between the two ends; 
R is the radius; 
η is the viscosity and  
L is the length of the tube.  
According to the Poiseuille’s equation, one can say that if the pressure difference, the 
viscosity and the length of the tube are constant, then the transfer speed is proportional to 
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the diameter. Additionally if the pressure difference, the viscosity and the diameter are 
constant, then the transfer speed is inversely proportional to the length of the tube. Since 
the radius is the fourth potency in relation to the length one can say that the radius has 
more influence on the transfer speed as the length. Although tube B does not have the 
shortest length, it was the tube with the fastest transfer speed since it has a wider diameter 
than the other tubes and it is also why the ANOVA test showed a statistical difference of 
tube B in relation to the other tubes.  
8.1.  Advantages of a combined thawing and transfer tube 
The advantages of replacing the current single thawing and single transfer disposable 
tubes by a combined thawing and transfer disposable tube are: there is no need for the use 
of two different disposable tubes, the single thawing and single transfer disposable tubes 
are combined in one disposable tube. Furthermore, there is a reduction on the quality risks 
since the manual handling of the adapter is no longer required and therefore the process 
is from the microbiological point of view more secure. Another advantage is the reduced 
assembling time as the removal of the transfer tube, the assembly of the adapter and of 
the transfer disposable tube are no longer needed (see figure 59). Moreover, if a combined 
thawing and transfer disposable tube with the possibility for flushing is chosen, the safety 
of ADCs will be improved.  
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8.2. Disadvantages of a combined thawing and transfer tube 
One of the disadvantages of a combined thawing and transfer disposable tube is that the 
more complex the disposable is, the more expensive it probably becomes. Moreover, it 
needs probably also more qualifications and it is more difficult to find a second supplier. 
Additionally, due to the complexity of the disposable the shelf life can be diminished.  
Figure 59. Cryo-vessel process cycle in Roche Diagnostics GmbH, Mannheim with the application 
of a combined thawing and transfer disposable tube 
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To evaluate if a disposable technology is feasible the following steps can be followed: 
 
 
 
 
 
 
8.3. Selection of an adequate combined thawing and transfer disposable 
tube 
The literature review and the results showed that a combined thawing and transfer 
disposable tube can be designed in accordance with the customer's wishes allowing the 
possibility of choosing the tubing material, the diameter of the tubes, the length of the 
tubes, the connectors and other requirements. Thus, a combined thawing and transfer 
disposable tube can be adapted and optimized to the customer's needs.  
To decide what kind of combined thawing and transfer tube should be designed a balance 
between Quality-Time-Cost should be taken into account and therefore, some factors 
have to be considered. 
It is necessary to know what kind of product will be manufactured so that the disposable 
ensures the safety of the operators and of the environment.  
Additionally, it must be considered what kind of method should be used for the transfer 
process, a pump or overpressure, since the tubing material has to be chosen.  
The selection of the method for the transfer process has to take into account the quality 
and efficiency (time and costs). Therefore, the method to be chosen is the one that is faster 
and that results in less shear forces to prevent protein aggregation and the formation of 
particles and that guarantees a product with at least the quality that existed before using 
disposables.  
There are a variety of polymeric materials available for tubing with different performance 
characteristics. The choice depends on what the customer wants. For example if the 
chosen method for transfer is a pump then it has to be taken in consideration if the tube 
Figure 60. Steps that can be followed to evaluate if a disposable technology is feasible from the business 
point of view in GMP-environment (Repetto, R., et al., 2014). 
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has been tested and meets the needed standards and if it has an extended pump life. If the 
chosen method for transfer is overpressure then it is important to choose a tube that has 
been tested and meets the required standards and that can withstand the applied pressure. 
According to the tested tubes a combination of different materials was also used with the 
aim to achieve different performances.  
However, the selected tubing materials should always be tested and qualified for 
leachables and extractables in order to prevent product contamination and guarantee the 
safety and quality of API solutions. Besides choosing the tubing materials, the diameter 
and length have also to be determined. The tubing has to have an appropriate diameter 
and length since it affects the transfer speed and therefore the efficiency. Moreover, the 
diameter has to be chosen so that the tube fits in the peristaltic pump of the thawing station 
and if the chosen method for the transfer process is a pump it has also to fit in the pump 
of the compounding process. Furthermore, the tubing should have a suitable length so 
that it can be connected to the thawing station and also from the cryo-vessel to the 
compounding tank. Additionally, the length should also be suitable to prevent yield loss.  
The connectors that are attached to the tubing in order to permit the different connections, 
such as the connections to the cryo-vessel or to the compounding tank have to be chosen 
in accordance with the facility and the level of sterility that must be assured. They should 
protect the fluid path from microbiological contamination ensuring an aseptic process and 
additionally ensure that there are no leaks that can lead to product loss. Moreover an 
efficient connection should protect the operators and the surrounded environment. 
Another aspect that has to be considered is that the connectors can burst with overpressure 
compromising the fluid path. Therefore the choice of the connector and the applied 
pressure has to be considered. 
8.4.  Recommendation of a transfer method 
According to the literature some protein solutions that are shear-sensitive can be used 
with peristaltic pumps (Niazi, S. K., 2012). However, because of peristaltic pumps some 
tubing materials can release particles due to their poor abrasion resistance (Bahal, S. M., 
& Romansky, J. M., 2002; Colas, A., Malczewski, R., & Ulman, K., 2004). Moreover, 
pumps like piston pumps and peristaltic pumps can cause protein aggregation and the 
formation of protein particles due to shear forces (Wang, W., 1999; Bausch, U. J., 2008; 
Maggio, E. T., 2008; Roche Internal Report, 2008; Nayak, A., Colandene, J., Bradford, 
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V., & Perkins, M., 2011; Vázquez-Rey, M., & Lang, D. A., 2011; Ma, J. K., & Hadzija, 
B., 2013). 
Regarding the results of this master thesis it is better to use overpressure for the transfer 
of product as it is faster (efficiency), as proved in the experiments and according to the 
literature it minimizes the possibility of protein aggregation (quality) since only low to 
moderate pressure is used (Chang, B. S., & Yeung, B., 2010; Wang, W., Nema, S., & 
Teagarden, D., 2010; Meersman, F., Daniel, I., Bartlett, D. H., Winter, R., Hazael, R., & 
McMillain, P. F., 2013). Furthermore, there are no changes in the transfer method, once 
nowadays in Roche Mannheim, the transfer method that is used is overpressure. 
Therefore, fewer mistakes would probably be made by the operators ensuring quality. 
Nevertheless, obtaining stability data for each API solution that should be transferred is 
always required to test this hypothesis. Consequently, using overpressure is considered 
to be the best option for the transfer of product from the cryo-vessel to the compounding 
tank. 
8.5.  Recommendation of a combined thawing and transfer disposable 
tube 
To decide what kind of combined thawing and transfer disposable tube is most suitable 
to replace the current single thawing and single transfer tubes in Roche Diagnostic GmbH, 
Mannheim some advantages and disadvantages of the tested tubes are presented in the 
table below (see table 18). 
 
 
 
 
 
 
 
 
Table 18. Advantages and disadvantages of the tested tubes 
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According to the advantages and disadvantages presented in the table 18, although Tube 
B showed the best results in terms of transfer speed it can´t be used alone as a combined 
thawing and transfer disposable tube once it is a delivery tube for the connection of 
different cryo-vessels. It can only be used in combination with a combined thawing and 
transfer disposable tube. Therefore, Tube A is adequate to replace the current single 
thawing and single transfer disposable tubes if it is used for non-hazardous API, since it 
is not suitable for highly potent drugs. In addition it is already qualified. On the other 
hand, tube C is adequate to replace the current single thawing and single transfer 
disposable tubes as it has been specially designed for highly potent drugs and for Roche 
Diagnostics GmbH, Mannheim. Regardless of the decision both tubes have to be 
optimized in respect to the diameter and lengths.  
8.6. Future research 
Taking into consideration the time constraints and the master thesis deadline, only a 
number of experiments were performed. Therefore, some additional tests and parameters 
were not part of the evaluation process. 
First, it was not possible to evaluate if a combined thawing and transfer disposable tube 
is appropriate to all described types of cryo-vessels. Moreover, there is the need to see if 
this concept can be used in all Modules of Roche Diagnostic GmbH, Mannheim. 
Additionally, it must be tested if the combined thawing and transfer disposable tube is 
adequate for the thawing process and how it will be transported in the cryo-vessel from 
the API-group to the different Modules. Furthermore, only tube A is already qualified, 
therefore, if the choice is to use tube C qualification and validation have to be done from 
the start point of cGMP. At last, there are still GMP issues that have to be evaluated and 
the need of a cost-benefit analysis. 
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9. Conclusion 
In the pharmaceutical industry, concerns about quality, time and costs, make it necessary 
for companies to analyse their processes and look for available technologies which allow 
process optimization. There are different disposable technologies available in which 
companies are investing due to their benefits.  
In recent years, the pharmaceutical industry has developed new and more potent active 
pharmaceutical ingredients. The development of innovative active pharmaceutical 
ingredients, like antibody drug conjugates requires containment and appropriate 
equipment and methods to ensure quality, efficiency and safety. With disposable 
technologies it is possible to customize and therefore optimize the processes, handling 
steps and yields.  
As shown, the use of a combined thawing and transfer disposable tube makes it possible 
to diminish the quality risks of manual handling, to reduce assembling time and improve 
safety of antibody drug conjugates. Moreover, the transfer of active pharmaceutical 
ingredient solutions is possible through the use of the two methods tested, peristaltic 
pump and overpressure, whereas the overpressure transfer method proved to be faster and 
has according to the literature research probably fewer effects on the stability of proteins. 
Moreover, this is a transfer method that is already used in the described pharmaceutical 
production area. 
The decision of which combined thawing and transfer disposable tube should replace the 
current single thawing and single transfer disposable tubes must be made by the 
pharmaceutical company taking their needs into account. To conclude, the use of an 
optimized combined thawing and transfer disposable tube in combination with the 
overpressure transfer method would be an innovative process and would bring quality 
and efficiency to a pharmaceutical sterile drug product manufacturing process. 
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